Why the study?
Does mitral transcatheter edge-to-edge repair (M-TEER) reduce annualized heart failure hospitalizations in patients with secondary and primary mitral regurgitation?
Population
Patients with SMR and PMR
Comparison
M-TEER with third-generation MitraClip (NTR/XTR) compared to the year before treatment
Design
Prospective multicentre international single-arm post-market observational study registry
Key result
Mitral transcatheter edge-to-edge repair was associated with a significant 68% decrease in annualized heart failure hospitalizations compared to the year before treatment.
Authors
Loading...
May support M-TEER to lower HF hospitalizations in MR; leaves open need for randomized confirmation in primary and secondary disease.
Does mitral transcatheter edge-to-edge repair (M-TEER) reduce annualized heart failure hospitalizations in patients with secondary and primary mitral regurgitation?
Effect estimate: 68% decrease
M-TEER significantly reduces annualized heart failure hospitalizations in patients with mitral regurgitation, though residual risk remains high in those with specific baseline characteristics such as LVEF <40% and NYHA class III/IV.
Stein et al. (2024) conducted an editorial in Mitral regurgitation and heart failure. Mitral transcatheter edge-to-edge repair (M-TEER) vs. Year before treatment was evaluated on Annualized heart failure hospitalizations (68% decrease). Mitral transcatheter edge-to-edge repair was associated with a significant 68% decrease in annualized heart failure hospitalizations compared to the year before treatment.